A repurposed epilepsy drug called sultiame cut breathing interruptions during sleep by up to 50% in adults with moderate-to-severe obstructive sleep apnea, according to results from a major European phase 2 trial. The findings, published in The Lancet, represent the strongest evidence yet that a once-daily pill could offer a real alternative for the millions of patients who cannot tolerate or refuse to use CPAP machines. With no approved oral pharmacological treatments currently available for the condition, the results have intensified interest in whether a simple tablet could reshape how sleep apnea is managed.
What the FLOW Trial Found
The trial, named FLOW, was a multicentre, randomised, double-blind, placebo-controlled, dose-finding study conducted across multiple European sites. Investigators enrolled adults with moderate-to-severe obstructive sleep apnea (OSA) who were not using CPAP or any other positive airway pressure device. Participants received either 100 mg or 200 mg of sultiame once daily, or a placebo, over a four-week treatment period, as detailed in the primary trial report.
The main outcome was the apnea-hypopnea index (AHI), which counts how many times per hour a person’s breathing partially or fully stops during sleep. At the higher 200 mg dose, sutiame produced clear, dose-dependent reductions in AHI, with the investigators confirming that the greatest improvements occurred in the 200 mg group compared with placebo. An accompanying peer-reviewed analysis emphasized that these reductions were clinically meaningful, corresponding to roughly 40–50% fewer breathing interruptions in many participants.
Beyond AHI, the FLOW team examined secondary measures such as oxygen desaturation events and sleep architecture. Patients on the higher dose showed fewer drops in blood oxygen and modest improvements in sleep continuity, though these secondary outcomes were more variable. Importantly, the trial also found that sultiame’s effect was not limited to a narrow subgroup: benefits appeared across a spectrum of body-mass indices and baseline disease severities, suggesting the mechanism may be broadly applicable within the moderate-to-severe OSA population.
How Sultiame Works Against Sleep Apnea
Sultiame belongs to a class of drugs that inhibit carbonic anhydrase, an enzyme that helps regulate carbon dioxide levels in the blood. By partially blocking this enzyme, the drug increases sensitivity to carbon dioxide and stimulates the respiratory drive, essentially nudging the brain to keep sending “breathe” signals even when the upper airway tends to collapse during sleep. This pharmacologic approach contrasts with weight-loss agents and devices that physically open the airway, raising the possibility that a carbonic anhydrase inhibitor could be combined with other therapies rather than directly competing with them.
The idea of repurposing sultiame for sleep apnea has been building for several years. An earlier randomized placebo-controlled study in adults with OSA established that the drug was generally safe and tolerable in this population and produced clinically relevant AHI reductions in a subset of participants. That proof-of-concept research, published in a leading respiratory journal, helped define the dose ranges and side-effect profile that would be acceptable in a larger program.
Those early data, together with preclinical work on carbonic anhydrase inhibition and respiratory control, informed the design of the FLOW phase 2 trial. The study was prospectively listed on ClinicalTrials.gov, outlining the eligibility criteria, dosing strategy, and statistical plan before enrollment began. That registration, along with independent peer review of the final results, adds transparency and reduces the risk of selective reporting.
Why an Oral Option Matters Now
Obstructive sleep apnea is one of the most common chronic sleep disorders worldwide, marked by repeated airway collapse that fragments sleep and strains the cardiovascular system. CPAP machines, which deliver pressurized air through a mask, remain the standard first-line therapy and are highly effective when used consistently. Yet many patients struggle with mask discomfort, noise, nasal congestion, or claustrophobia, and real-world data show that a substantial proportion either use CPAP only a few hours per night or abandon it altogether.
The FLOW trial deliberately focused on adults who were not using CPAP or any other positive airway pressure device, reflecting the large group of patients who either cannot tolerate the equipment or have declined it. For these individuals, current options are limited to oral appliances, positional therapy, lifestyle changes, and in some cases surgery, each with its own constraints. A once-daily pill that directly improves nocturnal breathing would therefore fill a conspicuous gap in the treatment landscape.
Regulators have begun to recognize the need for additional tools. In late 2024, the U.S. Food and Drug Administration approved tirzepatide, marketed as Zepbound, as the first medication indicated for obstructive sleep apnea in adults with obesity, after earlier authorizing it for chronic weight management. According to the FDA’s public summary, tirzepatide improves OSA primarily by driving substantial weight loss rather than by directly modulating respiratory control.
That distinction matters. Not all people with OSA are overweight, and even among those who are, some may prefer a daily pill to a weekly injection or may not achieve sufficient weight loss to normalize breathing. If later-stage trials confirm the FLOW findings, sultiame would be the first oral therapy designed to act directly on the neural and chemical pathways that govern breathing stability during sleep, potentially complementing weight-loss strategies instead of replacing them.
Limits of the Current Evidence
Despite the encouraging results, the FLOW data have important limitations. The treatment period lasted just four weeks, far too short to determine whether the benefits persist over months or years of nightly use. OSA is typically a lifelong condition, and any pharmacologic alternative to CPAP will need to demonstrate durable effects as well as long-term safety, including potential impacts on kidney function, acid–base balance, and other systems influenced by carbonic anhydrase inhibition.
As a phase 2 study, FLOW was designed primarily to refine dosing and confirm a biological signal, not to prove that sultiame reduces cardiovascular events, accidents, or mortality. Larger phase 3 trials will need to address those endpoints and include more diverse populations, including patients with significant comorbidities. The main publication notes that the research was funded by Desitin Arzneimittel, the German company that manufactures sultiame, a standard arrangement in drug development but one that warrants careful attention to independent replication and transparent reporting.
Another caveat is that response to therapy was heterogeneous. While many participants experienced substantial reductions in AHI, others had more modest changes, and a minority did not improve meaningfully at all. That pattern echoes the earlier proof-of-concept trial, which also found that only a subset of patients derived large benefits. Future research will need to clarify which physiological traits (such as arousal threshold, loop gain, or airway collapsibility) predict response, so clinicians can target treatment to those most likely to benefit.
Safety will also be scrutinized as development advances. In FLOW, most adverse events were mild to moderate, with common complaints including paresthesia, taste disturbances, and gastrointestinal symptoms, consistent with the known profile of carbonic anhydrase inhibitors. However, rare but serious complications might not emerge until thousands of patients have been treated for longer periods. An ongoing phase 3 program, listed under a separate registration, is expected to provide more definitive data on both efficacy and safety across a broader population.
What Comes Next for Sultiame and Sleep Apnea Care
The FLOW trial marks a pivotal step in the search for pharmacologic treatments for obstructive sleep apnea, but it is not the final word. To move from promising experimental therapy to routine clinical option, sultiame will need to clear several hurdles: confirmation of benefit in large, diverse phase 3 trials; demonstration of long-term safety and adherence; and evidence that improvements in AHI translate into better daytime functioning and reduced cardiovascular risk.
Even if those conditions are met, sultiame is unlikely to replace CPAP outright. Instead, clinicians may eventually view it as part of a growing toolkit that includes weight-loss medications, mandibular advancement devices, positional strategies, and upper-airway surgery. For some patients, a pill might serve as a primary therapy; for others, it could be combined with lower-pressure CPAP or an oral appliance to improve comfort and adherence. The broader lesson from FLOW is that OSA, long treated almost exclusively with mechanical devices, may finally be entering an era where targeted pharmacology plays a meaningful role.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
